Here are 18 points of comparison from Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet, Smith+Nephew and NuVasive.
Medtronic (fourth quarter of the FY)
1. Revenue: $6 billion (26 percent decline)
2. Restorative therapy group, including spine, revenue: $7.725 billion (5.6 percent decline)
3. Spine revenue: $480 million (31 percent decline)
Johnson & Johnson Orthopedics
1. Sales: $2 billion (7.5 percent decline)
2. Trauma sales: $654 million (4.5 percent decline)
3. Spine, sports and other: $703 million (10 percent decline)
Stryker
1. Net sales: $3.6 billion (2 percent increase)
2. Orthopedic sales: $1.2 billion (2.1 percent decline)
3. Spine and nanotechnology sales: $700 million (0.7 percent increase)
Zimmer Biomet
1. Net sales: $1.78 billion (9.7 percent decline)
2. Net loss: $509 million
3. Spine, Dental, craniomaxillofacial revenue: $252 million (12.4 percent decline)
Smith+Nephew
1. Revenue: $1.1 billion (7.6 percent decline)
2. Orthopedic revenue: $497 million (9 percent decline)
3. Sports medicine and ENT revenue: $328 million (11 percent decline)
NuVasive
1. Revenue: $259.9 million (5.4 percent decline)
2. Net income: $5.3 million (43.6 percent decline)
3. The company made executive compensation cuts and pulled back on discretionary spending due to the pandemic.
More articles on devices:
Medtronic’s pipeline includes spine, robotics innovations despite pandemic setbacks
3 spine, neurosurgery device recalls in the past year
Aetna to cover sacroiliac joint fusion under new policy
